1.World Bank: Country and Lending Groups. http://data.worldbank.org/income-level/low-and-middle-income (2016). Accessed 18 sep 2016.
2.Mallewa M, Wilmshurst JM: Overview of the Effect and Epidemiology of Parasitic Central Nervous System Infections in African Children. Seminars in Pediatric Neurology 2014, 21(1):19–25.
3.Steel Z, Marnane C, Iranpour C, Chey T, Jackson JW, Patel V, Silove D: The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. International Journal of Epidemiology 2014, 43(2):476–493.
4.Centers for Disease Control and prevention - National Center for Chronic Diseases Prevention and Health Promotion: Mental Health and Chronic Diseases. National Healthy Worksites (NHW). https://www.cdc.gov/workplacehealthpromotion/tools-resources/pdfs/issue-brief-no–2-mental-health-and-chronic-disease.pdf (2012). Accessed 18 Sep 2016.
5.Aillon J-L, Ndetei DM, Khasakhala L, Ngari WN, Achola HO, Akinyi S, Ribero S: Prevalence, types and comorbidity of mental disorders in a Kenyan primary health centre. Social Psychiatry and Psychiatric Epidemiology 2014, 49:1257–1268.
6.Zoller T, Fèvre EM, Welburn SC, Odiit M, Coleman PG: Analysis of risk factors for T. brucei rhodesiense sleeping sickness within villages in south-east Uganda. BMC infectious diseases 2008, 8:88.
7.Okia M, Mbulamberi DB, De Muynck A: Risk factors assessment for T. b. rhodesiense sleeping sickness acquisition in S. E. Uganda. A case-control study. Annales De La Societe Belge De Medecine Tropicale 1994, 74:105–112.
8.Rostami A, Seyyedtabaei SJ, Aghamolaie S, Behniafar H, Lasjerdi Z, Abdolrasouli A, Mehravar S, Alvarado-Esquivel C: Seroprevalence and risk factors associated with toxoplasma gondii infection among rural communities in northern iran. Revista Do Instituto De Medicina Tropical De Sao Paulo 2016, 58:70.
9.Nourollahpour Shiadeh M, Rostami A, Pearce BD, Gholipourmalekabadi M, Newport DJ, Danesh M, Mehravar S, Seyyedtabaei SJ: The correlation between Toxoplasma gondii infection and prenatal depression in pregnant women. European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 2016, 35:1829–1835.
10.Vigo D, Thornicroft G, Atun R: Estimating the true global burden of mental illness. The Lancet Psychiatry 2016, 3:171–178.
11.Aillon J-L, Ndetei DM, Khasakhala L, Ngari WN, Achola HO, Akinyi S, Ribero S: Prevalence, types and comorbidity of mental disorders in a Kenyan primary health centre. Social Psychiatry and Psychiatric Epidemiology 2014, 49:1257–1268.
12.Blakemore A, Dickens C, Guthrie E, Bower P, Kontopantelis E, Afzal C, Coventry PA: Depression and anxiety predict health-related quality of life in chronic obstructive pulmonary disease: systematic review and meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:501–512.
13.Elsheikha HM, Büsselberg D, Zhu X-Q: The known and missing links between Toxoplasma gondii and schizophrenia. Metabolic Brain Disease 2016, 31:749–759.
14.World Health Organization: World Health Report 2001 - Mental Health: New Design, New Hope. WHO. Geneva: WHO library; 172p. 2001. http://www.who.int/whr/2001/media_centre/press_release/fr/. Accessed 13 sept 2017.
15.World Health Organization: Chapter 2: Impact of mental and behavioural disorders. http://www.who.int/whr/2001/chapter2/fr/index5.html. Accessed 24 apr 2017.
16.Haute Autorité de Santé: Guidance Note. Multi-annual programme on psychiatry and mental health. 2013. http://www.has-sante.fr/portail/ upload/docs/application/ pdf/2014–01/2013_10_08_programme_sante_ mentale_college.pdf. Accessed 24 apr 2017.
17.World Health Organization: World Malaria Report 2015. Geneva; WHO library; 280p. 2015. http://www.who.int/malaria/publications/world-malaria-report–2015/report/en/. Accessed 13 Mar 2019.
18.Institut Pasteur: Chagas disease. Institut Pasteur. 2015. https://www.pasteur.fr/fr/centre-medical/fiches-maladies/maladie-chagas. Accessed 23 Apr 2017.
19.Nicoletti A: Chapter 16 - Toxocariasis. In: Handbook of Clinical Neurology. Volume 114, edn. Edited by Hector H. Garcia HBTaOHDB: Elsevier; 2013: 217–228.
20.Magnaval JF, Glickman LT, Dorchies P, Morassin B: Highlights of human toxocariasis. Korean Journal of Parasitology 2001, 39:1–11.
21.Kenny JV, MacCabe RJ, Smith HV, Holland C: Serological evidence for the presence of toxocariasis in the Turkana District of Kenya. Transactions of the Royal Society of Tropical Medicine and Hygiene 1995, 89:377–378.
22.Chieffi PP, Ueda M, Camargo ED, de S, Guedes ML, Gerbi LJ, Spir M, Moreira AS: Visceral larva migrans: a seroepidemiological survey in five municipalities of São Paulo state, Brazil. Revista do Instituto de Medicina Tropical de Sao Paulo 1990, 32:204–210.
23.Damian MM, Martins M, Sardinha JF, De S, Chaves A, Tavares ADM: Frequency of the antibody anti-Toxocara canis in a community along the Uatumã River, State of Amazonas. Revista da Sociedade Brasileira de Medicina Tropical 2007, 40:661–664.
24.Park HY, Lee SU, Huh S, Kong Y, Magnaval JF: A seroepidemiological survey for toxocariasis in apparently healthy residents in Gangwon-do, Korea. Korean Journal of Parasitology 2002, 40:113–117.
25.Hayashi E, Tuda J, Imada M, Akao N, Fujita K: The high prevalence of asymptomatic Toxocara infection among schoolchildren in Manado, Indonesia. Southeast Asian Journal of Tropical Medicine and Public Health 2005, 36:1399–1406.
26.SANOFI. Sanofi’s commitment to the fight against sleeping sickness. In: Le Hub. 2017. https://lehub.sanofi.com/fr/acces-aux-soins/maladie-du-sommeil/. Accessed 24 apr 2017.
27.Flegr J: Predictors of Toxoplasma gondii infection in Czech and Slovak populations: the possible role of cat-related injuries and risky sexual behavior in the parasite transmission. Epidemiology and Infection 2017, 145:1351–1362.
28.Bouteille B: Epidemiology of cysticercosis and neurocysticercosis. Medecine Et Sante Tropicales 2014, 24:367–374.
29.World Health Organization: Working to overcome the global impact of neglected tropical diseases: first WHO report on neglected tropical diseases. Geneva: Department of Reproductive health and Research, World Health Organization; 2010.
30.Alvarado-Esquivel C: Toxocara Infection in Psychiatric Inpatients: A Case Control Seroprevalence Study. PLOS ONE 2013, 8:e62606.
31.Cong W, Zhang X-X, Zhou N, Yu C-Z, Chen J, Wang X-Y, Li B, Qian A-D, Zhu X-Q: Toxocara Seroprevalence among Clinically Healthy Individuals, Pregnant Women and Psychiatric Patients and Associated Risk Factors in Shandong Province, Eastern China. PLoS Neglected Tropical Diseases 2014, 8.
32.Abdoli A, Dalimi A, Arbabi M, Ghaffarifar F: Neuropsychiatric manifestations of latent toxoplasmosis on mothers and their offspring. Journal of Maternal-Fetal and Neonatal Medicine 2014, 27:1368–1374.
33.Forlenza OV, Vieira Filho AH, Machado LR, Nóbrega JP, de Barros NG: Depressive disorders associated with neurocysticercosis: prevalence and clinical correlations. Arquivos de neuro-psiquiatria 1998, 56:45–52.
34.Ramírez-Bermudez J, Corona T: Neuropsiquiatic manifestation in cerebral cysticercosis. Archivos de Neurociencias 2005, 10:92–94.
35.Wiwanitkit V: Dementia and neurocysticercosis. Acta Neurologica Taiwanica 2014, 23:1–3.
36.Centers for Disease Control and prevention - National Center for Chronic Diseases Prevention and Health Promotion: Mental Health and Chronic Diseases. National Healthy Worksites (NHW). https://www.cdc.gov/workplacehealth promotion/tools-resources/pdfs/issue-brief-no–2-mental-health-and-chronic-disease.pdf (2012). Accessed 18 sep 2016.
37.Daré LO, Bruand P-E, Gérard D, Marin B, Lameyre V, Boumédiène F, Preux P-M: Co-morbidities of mental disorders and chronic physical diseases in developing and emerging countries: a meta-analysis. BMC Public Health 2019, 19(1):304.
38.Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008–2012.
39.Moher D., Shamseer L., Ghersi D., Liberati A., Petticrew M., Shekelle P., et al. PRISMA for systematic review protocols (PRISMA-P). http://prisma-statement.org/Extensions/Protocols.aspx. Accessed 30 oct 2016.
40.National Collaborating Centre for Methods and Tools: Quality Checklist for Health Care Intervention Studies. Hamilton, On : McMaster University: Meta-analysis in medical research. (2008). http://www.nccmt.ca/resources/ search/9. Accessed 23 mar 2017.
41.Downs SH, Black N: The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. Journal of Epidemiology and Community Health 1998, 52:377–384.
42.CMA Manuals: Comprehensive Meta-Analysis Software. (2017). https://www.meta-analysis.com/pages/cma_manual.php. Accessed 31 mar 2017.
43.Borenstein M, Larry V. H, Julian P. T. H, Hannah R. R: Introduction to Meta-Analysis -. Oxford: Wiley; 2009.
44.Boyle MH: Guidelines for evaluating prevalence studies. Evidence-Based Mental Health 1998, 1:37–39.
45.Borenstein M, Hedges LV, Higgins JPT, Rothstein HR: A basic introduction to fixed-effect and random-effects models for meta-analysis. Research Synthesis Methods 2010, 1:97–111.
46.Borenstein M, Larry V. H, Julian P. T. H, Hannah R. R. Introduction to forest plots.Oxford: Wiley, 2009.44.Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ: British Medical Journal 1997, 315:629–634.
47.Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ: British Medical Journal 1997, 315:629–634.
48.Alipour A, Shojaee S, Mohebali M, Tehranidoost M, Abdi Masoleh F, Keshavarz H: Toxoplasma infection in schizophrenia patients: A comparative study with control group. Iranian Journal of Parasitology 2011, 6:31–37.
49.Alvarado-Esquivel C, Hernández-Tinoco J, Sánchez-Anguiano LF, Cisneros-Martínez JA: Low seroprevalence of Toxocara infection in schizophrenic inpatients in Durango, Mexico: A case control study. International Journal of Biomedical Science 2014, 10:269–271.
50.Alvarado-Esquivel C, Urbina-Álvarez JD, Estrada-Martínez S, Torres-Castorena A, Molotla-de-León G, Liesenfeld O, Dubey JP: Toxoplasma gondii infection and schizophrenia: a case control study in a low Toxoplasma seroprevalence Mexican population. Parasitology International 2011, 60:151–155.
51.Cetinkaya Z, Yazar S, Gecici O, Namli MN: Anti-Toxoplasma gondii antibodies in patients with schizophrenia—preliminary findings in a Turkish sample. Schizophrenia Bulletin 2007, 33:789–791.
52.Daryani A, Sharif M, Hosseini SH, Karimi SA, Gholami S: Serological survey of Toxoplasma gondii in schizophrenia patients referred to Psychiatric Hospital, Sari City, Iran. Tropical Biomedicine 2010, 27:476–482.
53.Emelia O, Amal RN, Ruzanna ZZ, Shahida H, Azzubair Z, Tan KS, Noor Aadila S, Siti NaM, Aisah MY: Seroprevalence of anti-Toxoplasma gondii IgG antibody in patients with schizophrenia. Tropical Biomedicine 2012, 29:151–159.
54.Esshili A, Thabet S, Jemli A, Trifa F, Mechri A, Zaafrane F, Gaha L, Juckel G, Babba H, Bel Hadj Jrad B: Toxoplasma gondii infection in schizophrenia and associated clinical features. Psychiatry Research 2016, 245:327–332.
55.Forlenza OV, Filho AH, Nobrega JP, dos Ramos Machado L, de Barros NG, de Camargo CH, da Silva MF: Psychiatric manifestations of neurocysticercosis: a study of 38 patients from a neurology clinic in Brazil. Journal of Neurology, Neurosurgery, and Psychiatry 1997, 62:612–616.
56.Hamidinejat H, Ghorbanpoor M, Hosseini H, Alavi SM, Nabavi L, Jalali MHR, Borojeni MP, Jafari H, Mohammadaligol S: Toxoplasma gondii infection in first-episode and inpatient individuals with schizophrenia. International Journal of Infectious Diseases 2010, 14:e978-e981.
57.Juanah LY, Jalaludin J, Osman M, Osman ZJ: Seroprevalence of Toxoplasma Gondii among schizophrenics at Hospital Kajang. American Journal of Infectious Diseases 2013, 9:11–16.
58.Kaplan M, Kalkan A, Kuk S, Demirdag K, Ozden M, Kilic SS: Toxocara seroprevalence in schizophrenic patients in Turkey. Yonsei Medical Journal 2008, 49:224–229.
59.Karabulut N, Bilgiç S, Gürok MG, Karaboğa F: Is there any role of latent toxoplasmosis in schizophrenia disease? Journal of the Chinese Medical Association 2015, 78:533–537.
60.Khademvatan S, Khajeddin N, Izadi S, Saki J: Study of Toxoplasma gondii infection in patients with bipolar disorder. Journal of Medical Sciences (Faisalabad) 2013, 13:215–220.
61.Khademvatan S, Saki J, Khajeddin N, Izadi-Mazidi M, Beladi R, Shafiee B, Salehi Z: Toxoplasma gondii exposure and the risk of schizophrenia. Jundishapur Journal of Microbiology 2014, 7.
62.Kheirandish F, Nazari H, Mahmoudvand H, Yaseri Y, Tarahi MJ, Fallahi S, Ezatpour B: Possible link between toxoplasma gondii infection and mood disorders in Lorestan province, Western Iran. Archives of Clinical Infectious Diseases 2016, 11.
63.Omar A, Bakar OC, Adam NF, Osman H, Osman A, Suleiman AH, Manaf MRA, Selamat MI: Seropositivity and serointensity of Toxoplasma gondii antibodies and DNA among patients with schizophrenia. The Korean Journal of Parasitology 2015, 53:29–34.
64.Ozaki Y, Guariento ME, de Almeida EA: Quality of life and depressive symptoms in Chagas disease patients. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation 2011, 20:133–138.
65.Tamer GS, Dundar D, Yalug I, Caliskan S, Yazar S, Aker A: The schizophrenia and Toxoplasma gondii connection: infectious, immune or both? Advances in therapy 2008, 25:703–709.
66.Stolic RV, Trajkovic GZ, Mihailovic B, Sipic MV, Celic DB, Lazic SF, Nikolic GR, Sovtic SR, Stolic DZ: Characteristics of depression in obese people living in an insecure environment. Indian Journal of Medical Sciences 2010, 64:307–314.
67.Kirkil G, Deveci F, Deveci SE, Atmaca M: Anxiety and depression symptoms in patients with chronic obstructive pulmonary disease (copd). Klinik Psikofarmakoloji Bulteni 2015, 25:151–161.
68.Aghanwa HS, Erhabor GE: Specific psychiatric morbidity among patients with chronic obstructive pulmonary disease in a Nigerian general hospital. Journal of Psychosomatic Research 2001, 50:179–183.
69.Fanger PC, Azevedo RCSd, Mauro MLF, Lima DD, Gaspar KC, Silva VFd, Nascimento WTJd, Botega NJ: [Depression and suicidal behavior of cancer inpatients: prevalence and associated factors]. Revista Da Associacao Medica Brasileira (1992) 2010, 56:173–178.
70.Hong JS, Tian J: Prevalence of anxiety and depression and their risk factors in Chinese cancer patients. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 2014, 22:453–459.
71.Huang Y, Chen J, Yang J, Song K, Wang X, Cheng X, Qu S: Evaluation of depressive symptoms in obese patients with or without acanthosis nigricans. Hormones (Athens, Greece) 2015, 14:417–424.
72.Islam SMS, Ferrari U, Seissler J, Niessen L, Lechner A: Association between depression and diabetes amongst adults in Bangladesh: a hospital based case-control study. Journal of Global Health 2015, 5:020406.
73.Mollaoglu H, Ucok K, Kaplan A, Genc A, Mayda H, Guzel HI, Sener U, Uygur E, Ozbulut O: Association analyses of depression, anxiety, and physical fitness parameters in Turkish obese adults. Journal of Back and Musculoskeletal Rehabilitation 2012, 25:253–260.
74.Negi H, Sarkar M, Raval AD, Pandey K, Das P: Presence of depression & its risk factors in patients with chronic obstructive pulmonary disease. The Indian Journal of Medical Research 2014, 139:402–408.
75.Yildirim A, Hacihasanoǧlu Aşilar R, Bakar N, Demir N: Effect of anxiety and depression on self-care agency and quality of life in hospitalized patients with chronic obstructive pulmonary disease: A questionnaire survey. International Journal of Nursing Practice 2013, 19:14–22.
76.Zhao L, Li X, Zhang Z, Song C, Guo C, Zhang Y, Zhang Y, Li L, Lu G, Zheng G et al: Prevalence, correlates and recognition of depression in Chinese inpatients with cancer. General Hospital Psychiatry 2014, 36:477–482.
77.World Health Organization: Good Laboratory Practice: Quality Practices for Regulated Non-clinical Research and Development. Geneva: WHO library; 232p. 2010.
78.Amerio A, Stubbs B, Odone A, Tonna M, Marchesi C, Nassir Ghaemi S: Bipolar I and II Disorders; A Systematic Review and Meta-Analysis on Differences in Comorbid Obsessive-Compulsive Disorder. Iranian Journal of Psychiatry and Behavioral Sciences 2016, 10.
79.Zhu S, Guo M-F, Feng Q-C, Fan J-M, Zhang L-X: Epidemiological evidences from China assume that psychiatric-related diseases may be associated with Toxoplasma gondii infection. Neuroendocrinology Letters 2007, 28:115–120.
80.Arias I, Sorlozano A, Villegas E, de Dios Luna J, McKenney K, Cervilla J, Gutierrez B, Gutierrez J: Infectious agents associated with schizophrenia: a meta-analysis. Schizophrenia Research 2012, 136:128–136.
81.de Barros JLVM, Barbosa IG, Salem H, Rocha NP, Kummer A, Okusaga OO, Soares JC, Teixeira AL: Is there any association between Toxoplasma gondii infection and bipolar disorder? A systematic review and meta-analysis. Journal of Affective Disorders 2017, 209:59–65.
82.Sutterland AL, Fond G, Kuin A, Koeter MWJ, Lutter R, van Gool T, Yolken R, Szoke A, Leboyer M, de Haan L: Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. Acta Psychiatrica Scandinavica 2015, 132:161–179.
83.Toftegaard KL, Gustafsson LN, Uwakwe R, Andersen UA, Becker T, Bickel GG, Bork B, Cordes J, Frasch K, Jacobsen BA et al: Where are patients who have co-occurring mental and physical diseases located? The International Journal of Social Psychiatry 2015, 61:456–464.
84.World Health Organization: Mental Health Action Plan 2013–2020. Geneva: WHO Library Cataloguing-in-Publication Data; 50p.2013.